Shenzhiling Oral Liquid Protects STZ-Injured Oligodendrocyte through PI3K/Akt-mTOR Pathway

Figure 8

The role of rapamycin on protective effect of SZL-medicated serum on STZ-injured OLN-93 cells. (a) Effect of rapamycin on SZL-medicated serum-increased cell viability of injured OLN-93 cells. Effect of rapamycin on SZL-medicated serum-induced upregulation of p-mTOR (b) and MBP (c, d) in injured OLN-93 cells. C, control group; M, model group; M + RAPA, model + rapamycin group; Don, donepezil group; Don + RAPA, donepezil + rapamycin group; SZL, SZL-medicated serum group; SZL + RAPA, SZL-medicated serum + rapamycin group. , significantly different from control group; and , significantly different from model group; and , significantly different from donepezil group; , significantly different from SZL-medicated serum group. Each point represents the mean ± SD of n = 6 experiments.

(a)

(b)

(c)

(d)